Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation
Saved in:
Main Authors: | Girish Gilly Munavalli, MD, MHS, FACMS (Author), Siri Knutsen-Larson, MD (Author), Mary P. Lupo, MD (Author), Roy G. Geronemus, MD (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2021-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Delayed inflammatory reaction to hyaluronic acid filler following Shingrix and Fluzone vaccines treated with lisinopril
by: Jacqueline Witt, MD, et al.
Published: (2022) -
Dietary Potassium Downregulates Angiotensin-I Converting Enzyme, Renin, and Angiotensin Converting Enzyme 2
by: Carlos P. Vio, et al.
Published: (2020) -
Angiotensin-converting enzyme inhibitors
by: David García Barreto, et al.
Published: (2014) -
Chitotriosidase: Providing confirmation of cutaneous sarcoidosis when angiotensin converting enzyme fails
by: Carlie Reeves, BA, MS, et al.
Published: (2024) -
Tissue Angiotensin II Generating System by Angiotensin-Converting Enzyme and Chymase
by: Mizuo Miyazaki, et al.
Published: (2006)